z-logo
open-access-imgOpen Access
Efficient gene expression signature for a breast cancer immuno-subtype
Author(s) -
Ben Galili,
Xavier Tekpli,
Vessela Kristensen,
Zohar Yakhini
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0245215
Subject(s) - subtyping , breast cancer , oncology , cancer , signature (topology) , gene , biology , computational biology , medicine , computer science , genetics , mathematics , programming language , geometry
Motivation and background The patient’s immune system plays an important role in cancer pathogenesis, prognosis and susceptibility to treatment. Recent work introduced an immune related breast cancer. This subtyping is based on the expression profiles of the tumor samples. Specifically, one study showed that analyzing 658 genes can lead to a signature for subtyping tumors. Furthermore, this classification is independent of other known molecular and clinical breast cancer subtyping. Finally, that study shows that the suggested subtyping has significant prognostic implications. Results In this work we develop an efficient signature associated with survival in breast cancer. We begin by developing a more efficient signature for the above-mentioned breast cancer immune-based subtyping. This signature represents better performance with a set of 579 genes that obtains an improved Area Under Curve (AUC). We then determine a set of 193 genes and an associated classification rule that yield subtypes with a much stronger statistically significant (log rank p-value < 2 × 10 −4 in a test cohort) difference in survival. To obtain these improved results we develop a feature selection process that matches the high-dimensionality character of the data and the dual performance objectives, driven by survival and anchored by the literature subtyping.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here